UY36761A - Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma - Google Patents

Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma

Info

Publication number
UY36761A
UY36761A UY0001036761A UY36761A UY36761A UY 36761 A UY36761 A UY 36761A UY 0001036761 A UY0001036761 A UY 0001036761A UY 36761 A UY36761 A UY 36761A UY 36761 A UY36761 A UY 36761A
Authority
UY
Uruguay
Prior art keywords
solid oral
oral formulation
preparing
same
formulation containing
Prior art date
Application number
UY0001036761A
Other languages
English (en)
Inventor
Park Caleb Hyung Min
Jung Myeong Ki
Kim Jin Cheul
Kim Yong Il
Park Jae Hyun
Woo Jong Soo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY36761A publication Critical patent/UY36761A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Una formulación oral sólida que, como principio activo, incluye irinotecán o una de sus sales farmacéuticamente aceptables, y un agente acidificante.
UY0001036761A 2015-06-30 2016-06-30 Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma UY36761A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150093413A KR102293907B1 (ko) 2015-06-30 2015-06-30 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Publications (1)

Publication Number Publication Date
UY36761A true UY36761A (es) 2016-12-30

Family

ID=57608859

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036761A UY36761A (es) 2015-06-30 2016-06-30 Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma

Country Status (32)

Country Link
US (2) US11090299B2 (es)
EP (1) EP3300483B1 (es)
JP (2) JP6835746B2 (es)
KR (2) KR102293907B1 (es)
CN (1) CN107949375B (es)
AR (1) AR105203A1 (es)
AU (2) AU2016286804B2 (es)
BR (1) BR112017028468B1 (es)
CA (1) CA2988079C (es)
CL (1) CL2017003437A1 (es)
CO (1) CO2017013317A2 (es)
CR (1) CR20170604A (es)
DO (1) DOP2017000307A (es)
EC (1) ECSP17085443A (es)
ES (1) ES2930663T3 (es)
GT (1) GT201700280A (es)
HK (1) HK1246656A1 (es)
IL (1) IL256278B (es)
JO (1) JO3683B1 (es)
MX (2) MX2017014994A (es)
MY (1) MY191297A (es)
NZ (1) NZ737238A (es)
PE (1) PE20181040A1 (es)
PH (1) PH12017502376A1 (es)
RU (1) RU2716595C2 (es)
SA (1) SA517390602B1 (es)
SG (1) SG10201913274VA (es)
SV (1) SV2017005603A (es)
TW (2) TW202137985A (es)
UY (1) UY36761A (es)
WO (1) WO2017003120A1 (es)
ZA (1) ZA201708429B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
AU2021321092A1 (en) * 2020-08-06 2023-03-09 Sk Biopharmaceuticals Co., Ltd. Solid oral composition comprising carbamate compound, and preparation method therefor
WO2022076663A1 (en) 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CA2300892A1 (en) 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2002154963A (ja) 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
BR0308133A (pt) 2002-03-01 2005-01-04 Pharmacia Italia Spa Forma polimórfica cristalina de cloridrato de irinotecan
US20060030578A1 (en) 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (ja) 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
US20050208146A1 (en) 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
EP1798235B1 (en) * 2004-10-01 2015-04-01 Kabushiki Kaisha Yakult Honsha Acid addition salt of irinotecan
ES2755273T3 (es) 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
EP2266974A1 (en) 2005-05-23 2010-12-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
CN101283983A (zh) 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7880591B2 (en) 2008-02-01 2011-02-01 Apple Inc. Consumer abuse detection system and method
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102617584B (zh) 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CA2891346A1 (en) 2012-11-30 2014-06-05 Gossett Campbell Pharmaceutical composition comprising trametinib dimethyl sulfoxide
CA2973906C (en) 2014-01-17 2022-07-26 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
KR20170003143A (ko) 2017-01-09
CA2988079C (en) 2023-09-26
CN107949375B (zh) 2023-04-21
US20180153878A1 (en) 2018-06-07
PE20181040A1 (es) 2018-07-03
CO2017013317A2 (es) 2018-03-28
JP2021070705A (ja) 2021-05-06
SG10201913274VA (en) 2020-03-30
CA2988079A1 (en) 2017-01-05
TWI750125B (zh) 2021-12-21
CL2017003437A1 (es) 2018-06-22
CR20170604A (es) 2018-04-27
BR112017028468A2 (pt) 2018-08-28
NZ737238A (en) 2024-03-22
KR102293907B1 (ko) 2021-08-26
US11090299B2 (en) 2021-08-17
TW201713339A (zh) 2017-04-16
EP3300483A4 (en) 2018-12-12
RU2716595C2 (ru) 2020-03-13
EP3300483A1 (en) 2018-04-04
RU2017143849A3 (es) 2019-09-25
DOP2017000307A (es) 2018-03-15
MY191297A (en) 2022-06-14
IL256278A (en) 2018-02-28
US20210330666A1 (en) 2021-10-28
JP2018519279A (ja) 2018-07-19
AU2021204259A1 (en) 2021-07-22
AR105203A1 (es) 2017-09-13
BR112017028468B1 (pt) 2023-03-28
EP3300483B1 (en) 2022-11-09
AU2016286804B2 (en) 2021-03-25
HK1246656A1 (zh) 2018-09-14
PH12017502376B1 (en) 2018-06-25
SV2017005603A (es) 2018-03-12
ECSP17085443A (es) 2018-01-31
KR20210106946A (ko) 2021-08-31
AU2016286804A1 (en) 2017-11-30
ES2930663T3 (es) 2022-12-20
KR102317664B1 (ko) 2021-10-26
CN107949375A (zh) 2018-04-20
MX2017014994A (es) 2018-08-15
MX2021004439A (es) 2021-05-27
JP6835746B2 (ja) 2021-02-24
JO3683B1 (ar) 2020-08-27
GT201700280A (es) 2019-10-10
SA517390602B1 (ar) 2022-11-09
PH12017502376A1 (en) 2018-06-25
IL256278B (en) 2020-11-30
TW202137985A (zh) 2021-10-16
RU2017143849A (ru) 2019-08-01
ZA201708429B (en) 2019-06-26
WO2017003120A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
MX2017000254A (es) Sistema para la administracion de una composicion de higiene bucal.
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
BR112017004393A2 (pt) formulações de anticorpo
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EP3500291A4 (en) FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS
MX2016013236A (es) Formulacion inmunosupresora.
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
EA201691741A1 (ru) Фармацевтическая композиция
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
PH12016502527A1 (en) Stabilized desmopressin
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
WO2016112339A8 (en) Stable formulations for the oral administration of amphotericin b and related methods
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230821